Sangamo Therapeutics, Inc. (SGMO)

Market Cap	46.15M -72.1%
Revenue (ttm)	39.55M -31.6%
Net Income	-122.93M
EPS	-0.44
Shares Out	414.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,230,200
Average Volume	16,901,166
Open	0.1300
Previous Close	0.1400
Day's Range	0.1300 - 0.2200
52-Week Range	0.1051 - 0.7660
Beta	1.04
RSI	30.61
Earnings Date	May 7, 2026

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational ge...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 142
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGMO

Financial Performance

In 2025, Sangamo Therapeutics's revenue was $39.55 million, a decrease of -31.57% compared to the previous year's $57.80 million. Losses were -$122.93 million, 25.5% more than in 2024.